• Human APIs PowderRespiratory Drugs Raw Material Antiviral Antibacterial Antipyretic Analgesics Antihistamine Drugs Antineoplastic Cosmetic Raw Material
  • Pharmaceutical IntermediatesPharmaceutical intermediates Nutritional Supplements Pharmaceutical raw materials
  • OEM & ODMCapsule Softgel Capsule Gummies Drop & drinks Tables
  • Veterinary raw materialsAntibacterial anti-inflammatory Respiratory Drugs Anthelmintics Antiviral drugs Feed additives
  • About UsCompany profileQualificationQuality AssuranceService teamFactory TourR&D Center
  • Supply Obeticholic Acid raw Materials Powder

    • Supply Obeticholic Acid raw Materials Powder
    • Supply Obeticholic Acid raw Materials Powder storehouse
    • Supply Obeticholic Acid raw Materials Powder quality testing
    • Supply Obeticholic Acid raw Materials Powder quality testing
    • Supply Obeticholic Acid raw Materials Powder certificate

    Product Overview:

    Obeccholic acid is developed by Intercept Pharmaceutical Company in the United States, and its compound patent was applied for in the United States in 2001, patent number US7138390, and has not yet applied for compound patent in China. Obeccholic acid is the first drug developed in 20 years to treat cholestatic liver disease in patients who do not respond adequately to ursodeoxycholic acid or cannot tolerate it.

    Supply Obeticholic Acid raw Materials Powder Attributes

    Obeticholic Acid raw Materials Powder

    CAS:459789-99-2

    MF:C26H44O4

    Obeticholic Acid

    MW:420.63

    EINECS:810-245-2

    Specification​: 99% min Obeticholic Acid Powder

    Sample:Obeticholic Acid Powder

    Packaging:1kg/bag, 25kg/drum

    Brand: Henrikang

    Appearance:white

    Storage: Cool Dry Place

    Shelf Life: 2 Years

    Test Method: HPLC

    Supply Obeticholic Acid raw Materials Powder Details

    Obeticholic Acid Powder Usage and Synthesis.

    Obeticholic Acid, also known as 6-ethyl goosenodeoxycholic acid, is a novel derivative of goosenodeoxycholic acid (CDCA) in human primary bile acids and a natural ligand of farnesate derivative X receptor (FXR). Obecholic acid is a farnesol X receptor agonist, which indirectly inhibits cytochrome 7A1 (CYP7A1) gene expression by activating farnesol X receptor. Because CYP7A1 is a rate-limiting enzyme for cholic acid biosynthesis, obecholic acid can inhibit cholic acid synthesis and is used in the treatment of primary biliary cirrhosis and non-alcoholic fatty liver disease.

    Obeticholic Acid Powder

    Uses of Obeticholic Acid.

    Obeccholic acid tablets can inhibit the synthesis of cholic acid, promote bile secretion and reduce portal hypertension, and can play a role in the treatment of primary biliary cirrhosis, non-alcoholic fatty liver, primary sclerosing cholangitis and other diseases when prescribed by doctors.

    Obecholic acid tablet is a farnitol receptor agonist, which can indirectly inhibit the expression of cytochrome gene, thus inhibiting the synthesis of cholic acid, promoting bile secretion and reducing portal hypertension. Obeccholic acid tablets are often used to treat primary biliary cirrhosis, and can also be used to treat nonalcoholic fatty liver and primary sclerosing cholangitis. This product can be used alone or in combination with ursodeoxycholic acid, but patients with complete intestinal obstruction should contraindicate this product. The therapeutic effect of obecholic acid tablets is good, but some people will have adverse reactions after application, common adverse reactions include diarrhea, nausea, vomiting, abdominal pain and so on. However, these symptoms are usually temporary and usually resolve on their own after stopping the drug.

    During the use of aubecholic acid tablets, regular follow-up visits should be made with a doctor to ensure the effectiveness and safety of treatment.

    Obeticholic Acid

    Pharmacological action of Obeticholic Acid.

    PBC is a chronic cholestasis caused by bile duct dysplasia or bile acid metabolism disorder, which causes lipid dissolution of cell membrane, permeability change, cell content flow out, and eventually progress to liver fibrosis and cirrhosis. At present, ursodeoxycholic acid (URsodeoxycholic acid) is the main drug used in clinical treatment of PBC. Ursodeoxycholic acid stimulates hepatobiliary secretion through intracellular signaling molecule mitogen-activated protein kinase (MAPK) pathway, and protects epithelial cells from bile acid destruction.

    Product Method of Bulk Obeticholic Acid Powder.

    Our advantage
    Our Factory
    Shipping
    Tel: 86-29-89601602
    WhatsApp: 8615091775531
    WeChat: 15091775531
    E-mail: sales21@interlgroup.com
    Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
    ©2023 Xi'an Henrikang Biotech Co., Ltd.,